Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
作者： Giovanni Scambia , Giuseppe Curigliano , Sabino De Placido , Mariavittoria Locci , Ida Paris
DOI: 10.1016/J.EJCA.2021.02.035
关键词:
摘要: Abstract Background Poly (ADP-ribose) polymerase-inhibitors (PARPis) showed antitumour activity in BRCA1/2-mutated cancers, with more heterogeneous outcomes tumours harbouring mutations that impair other genes involved the DNA homologous recombination repair (HRR) or wild-type (wt). Methods We conducted a systematic review and meta-analysis to better assess role of PARPis treatment metastatic solid tumours, without BRCA1/2 mutations. The primary end-point was progression-free survival (PFS). secondary end-points were overall response rate (ORR) (OS). A random-effects model applied. Results Twenty-nine studies (8,839 patients) included. PFS significantly improved (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.51–0.68, p Conclusion Our results confirm efficacy already approved PARPi-based treatments BRCA1/2-mutant support their also BRCA-independent HRR-deficient suggest potentially broader some wt perhaps appropriate therapeutic partners. Prospective are warranted.
sci-hub.st 参考文章(81)
Taofeek K. Owonikoko, Suzanne E. Dahlberg, Gabriel L. Sica, Lynne I. Wagner, James L. Wade, Gordan Srkalovic, Bradley W. Lash, Joseph W. Leach, Ticiana B. Leal, Charu Aggarwal, Suresh S. Ramalingam, Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. Journal of Clinical Oncology. ,vol. 37, pp. 222- 229 ,(2017) , 10.1200/JCO.18.00264
Darren R. Hodgson, Brian A. Dougherty, Zhongwu Lai, Anitra Fielding, Lynda Grinsted, Stuart Spencer, Mark J. O’Connor, Tony W. Ho, Jane D. Robertson, Jerry S. Lanchbury, Kirsten M. Timms, Alexander Gutin, Maria Orr, Helen Jones, Blake Gilks, Chris Womack, Charlie Gourley, Jonathan Ledermann, J. Carl Barrett, Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes British Journal of Cancer. ,vol. 119, pp. 1401- 1409 ,(2018) , 10.1038/S41416-018-0274-8
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit Oza, Antonio González-Martín, Carol Aghajanian, William Bradley, Cara Mathews, Joyce Liu, Elizabeth S. Lowe, Ralph Bloomfield, Paul DiSilvestro, Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer The New England Journal of Medicine. ,vol. 379, pp. 2495- 2505 ,(2018) , 10.1056/NEJMOA1810858
Zafeiris Zafeiriou, Diletta Bianchini, Robert Chandler, Pasquale Rescigno, Wei Yuan, Suzanne Carreira, Maialen Barrero, Antonella Petremolo, Susana Miranda, Ruth Riisnaes, Daniel Nava Rodrigues, Bora Gurel, Semini Sumanasuriya, Alec Paschalis, Adam Sharp, Joaquin Mateo, Nina Tunariu, Arul M. Chinnaiyan, Colin C. Pritchard, Kevin Kelly, Johann S. de Bono, Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. European Urology. ,vol. 75, pp. 184- 192 ,(2019) , 10.1016/J.EURURO.2018.09.048
Todd A. Hopkins, William B. Ainsworth, Paul A. Ellis, Cherrie K. Donawho, Enrico L. DiGiammarino, Sanjay C. Panchal, Vivek C. Abraham, Mikkel A. Algire, Yan Shi, Amanda M. Olson, Eric F. Johnson, Julie L. Wilsbacher, David Maag, PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow. Molecular Cancer Research. ,vol. 17, pp. 409- 419 ,(2019) , 10.1158/1541-7786.MCR-18-0138
Vera Gorbunova, J. Thaddeus Beck, Ralf-Dieter Hofheinz, Pilar Garcia-Alfonso, Marina Nechaeva, Antonio Cubillo Gracian, Laszlo Mangel, Elena Elez Fernandez, Dustin A. Deming, Ramesh K. Ramanathan, Alison H. Torres, Danielle Sullivan, Yan Luo, Jordan D. Berlin, A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer British Journal of Cancer. ,vol. 120, pp. 183- 189 ,(2019) , 10.1038/S41416-018-0343-Z
Xuan Jiang, Xiaoying Li, Weihua Li, Huimin Bai, Zhenyu Zhang, PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. Journal of Cellular and Molecular Medicine. ,vol. 23, pp. 2303- 2313 ,(2019) , 10.1111/JCMM.14133
J.F. Liu, W.T. Barry, M. Birrer, J.-M. Lee, R.J. Buckanovich, G.F. Fleming, B.J. Rimel, M.K. Buss, S.R. Nattam, J. Hurteau, W. Luo, J. Curtis, C. Whalen, E.C. Kohn, S.P. Ivy, U.A. Matulonis, Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Annals of Oncology. ,vol. 30, pp. 551- 557 ,(2019) , 10.1093/ANNONC/MDZ018
ME Robson, N Tung, P Conte, S-A Im, E Senkus, B Xu, N Masuda, S Delaloge, W Li, A Armstrong, W Wu, C Goessl, S Runswick, SM Domchek, None, OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer Annals of Oncology. ,vol. 30, pp. 558- 566 ,(2019) , 10.1093/ANNONC/MDZ012
Roman M. Chabanon, Jean-Charles Soria, Christopher J. Lord, Sophie Postel-Vinay, Beyond DNA repair: the novel immunological potential of PARP inhibitors. Molecular and Cellular Oncology. ,vol. 6, pp. 1585170- ,(2019) , 10.1080/23723556.2019.1585170